Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

532
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
532
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

321
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
321
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

491
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
491
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

391
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
391
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

398
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same author

Recombinant human diamine oxidase prevents histamine-induced hypoxia, shock and death in guinea pigs.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2026
Same author

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
Same author

Endovascular thrombectomy with or without intravenous thrombolysis in large-vessel ischemic stroke: an updated meta-analysis.

Scientific reports·2026
Same author

Effects of an early restrictive versus liberal fluid strategy on long-term patient-centered outcomes in sepsis-induced hypotension: an open-label, randomized controlled trial.

American journal of respiratory and critical care medicine·2026
Same author

Abnormal whole-blood viscoelastic test results in patients with bleeding disorder of unknown cause.

Blood vessels, thrombosis & hemostasis·2026

Related Experiment Video

Updated: Feb 22, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.4K

Clopidogrel in Critically Ill Patients.

Christian Schoergenhofer1, Eva-Luise Hobl1, Peter Schellongowski2

  • 1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.

Clinical Pharmacology and Therapeutics
|September 16, 2017
PubMed
Summary
This summary is machine-generated.

Critically ill patients show poor response to clopidogrel due to insufficient drug metabolism. Alternative antiplatelet therapies may be more effective for these high-risk individuals.

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Related Experiment Videos

Last Updated: Feb 22, 2026

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness
09:17

Use of a Central Venous Line for Fluids, Drugs and Nutrient Administration in a Mouse Model of Critical Illness

Published on: May 2, 2017

9.4K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.7K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.5K

Area of Science:

  • Pharmacology
  • Critical Care Medicine
  • Cardiovascular Research

Background:

  • Limited data exist on clopidogrel treatment efficacy in critically ill patients.
  • Clopidogrel is a cytochrome P450 (CYP450) activated prodrug requiring adequate metabolism for therapeutic effect.
  • Critically ill patients represent a unique population with potentially altered drug metabolism and pharmacokinetics.

Purpose of the Study:

  • To investigate the effects and drug concentrations of clopidogrel in critically ill patients.
  • To assess the half-life of pantoprazole, a similarly metabolized drug, in this patient group.
  • To evaluate clopidogrel's metabolic profile and its impact on platelet inhibition in critical illness.

Main Methods:

  • ADP-induced whole blood aggregometry and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) assay were used to assess platelet response.
  • Plasma concentrations of clopidogrel prodrug and its active metabolite were measured.
  • Pantoprazole half-life was determined in a subset of critically ill patients.

Main Results:

  • A high proportion of critically ill patients were identified as poor responders to clopidogrel (74% by aggregometry, 65% by VASP-P assay).
  • In critically ill patients, clopidogrel parent drug levels exceeded active metabolite levels, indicating insufficient metabolization.
  • Pantoprazole half-life was significantly longer in critically ill patients compared to reference populations, supporting impaired drug metabolism.

Conclusions:

  • Critically ill patients exhibit insufficient metabolization of clopidogrel, leading to poor antiplatelet response.
  • Altered pharmacokinetics, evidenced by increased pantoprazole half-life, contribute to inadequate clopidogrel activation.
  • Alternative antiplatelet agents may be more suitable for achieving effective platelet inhibition in critically ill patients.